VistaGen Therapeutics Aktie

Kaufen

Verkaufen

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Bei einem anderen Broker handeln

WKNA2AJU8

ISINUS92840H2022

SymbolVTGN

VistaGen Therapeutics Aktien News

Sortieren:Datum Meistgelesen

14.01.25BusinesswireVistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

10.01.25BusinesswireVistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

14.11.24BusinesswireVistagen to Present at the Stifel 2024 Healthcare Conference

07.11.24BusinesswireVistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

05.11.24BusinesswireVistagen to Present at the 2024 Neuroscience Education Institute Congress

01.11.24BusinesswireVistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

09.10.24BusinesswireVistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

23.09.24BusinesswireVistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

13.08.24BusinesswireVistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

06.08.24BusinesswireVistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

09.07.24BusinesswireVistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

27.06.24BusinesswireVistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

11.06.24BusinesswireVistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

07.06.24BusinesswireVistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

29.05.24BusinesswireVistagen to Present at the Jefferies Global Healthcare Conference

23.05.24BusinesswireVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

07.05.24BusinesswireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

25.04.24BusinesswireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

09.04.24BusinesswireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

01.04.24BusinesswireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

11.03.24BusinesswireVistagen to Present at Stifel 2024 Virtual CNS Days

28.02.24BusinesswireVistagen to Present at TD Cowen 44th Annual Health Care Conference

13.02.24BusinesswireVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

06.02.24BusinesswireVistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024

27.12.23BusinesswireVistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

09.11.23BusinesswireVistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

08.11.23BusinesswireVistagen to Present at Stifel 2023 Healthcare Conference

07.11.23BusinesswireVistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences

06.11.23BusinesswireVistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023

05.10.23BusinesswireVistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

02.10.23BusinesswireVistagen Announces Pricing of $100 Million Underwritten Offering

12.09.23BusinesswireVistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

05.09.23BusinesswireVistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan

22.08.23BusinesswireVistagen Appoints Cindy Anderson as Chief Financial Officer

10.08.23BusinesswireSubsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results

10.08.23PR NewswireAffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

08.08.23BusinesswireVistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023

07.08.23BusinesswireVistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

17.07.23BusinesswireVistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain

13.07.23BusinesswireVistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

VistaGen Therapeutics News

VistaGen Therapeutics News: auf dieser Seite finden Sie alle VistaGen Therapeutics News und Nachrichten zur VistaGen Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch VistaGen Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um VistaGen Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.